Emerging evidence has suggested that B cells and humoral immunity could modulate the immune response to intracellular pathogens. We speak to Babak Javid about his research on this topic and the importance of learning about immune factors in order to develop vaccination strategies and to understand latent TB.
Recently, a research collaboration has managed to reverse HIV latency in infected CD4+ T cells in mouse and macaque models, exposing them to the body’s immune response.
Despite long-term antiretroviral therapy, cerebrospinal HIV reservoirs have been identified in individuals living with the virus and linked with a higher rate of cognitive defects.
A novel phage-based blood assay has demonstrated its potential for identifying people at high-risk of developing tuberculosis, in addition to diagnosing established cases.
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
Researchers from the Howard Hughes Medical Institute have developed a novel genetic tool for detecting fast and accurate measures of latent HIV.
Clinical trial data has proved a novel, short therapy more effective and safe for the treatment of latent tuberculosis than the standard therapy in both adults and children.
Take a look behind the scenes of a recent Future Virology article entitled ‘Latent vs productive infections: The alpha herpesvirus switch’ as we ask authors Lynn Enquist, Orkide Koyuncu and Margaret MacGibeny about latency, reactivation and the best models.
Researchers have developed a novel compound, L-HIPPO, which can prevent viral budding in HIV-infected cells. It has been suggested this compound could supplement existing ‘kick and kill’ strategies, allowing complete eradication of HIV in the body.
Interval dosing with Vorinostat could reverse HIV latency, however, additional measures are still required to achieve complete HIV reservoir depletion, study suggests.
